OÜ PharmaFiveRegistered
Key figures
5 285 923 €−5,0%
Revenue 2025
+18,8%
Average annual growth 2020–2025
Ratios
2025−0,1%
Profit margin
−0,1%
EBITDA margin
−175,2%
Equity ratio
0,4×
Current ratio
0,5%
Return on equity
804 €
Average gross salary
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
Quarterly figures
| Quarter | Revenue | Number of employees | Labour taxes |
|---|---|---|---|
| Q2 2026 | 1 256 774 € | 22 | 22 980 € |
| Q1 2026 | 1 285 059 € | 21 | 27 338 € |
| Q4 2025 | 1 264 544 € | 21 | 26 691 € |
| Q3 2025 | 1 186 255 € | 20 | 28 218 € |
| Q2 2025 | 1 442 004 € | 20 | 26 539 € |
| Q1 2025 | 1 456 071 € | 23 | 23 490 € |
Source: Tax Board open data — based on VAT returns, may not exactly match revenue in the annual report. Updated quarterly.
Dividends
calculated2025
No dividends were distributed.
History
20250 €
20240 €
2023 ~134 078 €
20220 €
20210 €
Previous year's retained earnings + previous year's profit − current retained earnings.
Summary of financial statements2020–2025
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Balance sheet — assets | ||||||
| Total current assets | 990 986 | 851 219 | 794 930 | 950 552 | 804 448 | 626 803 |
| Total non-current assets | 1 487 804 | 1 350 900 | 1 190 990 | 4839 | 2636 | 0 |
| Total assets | 2 478 790 | 2 202 119 | 1 985 920 | 955 391 | 807 084 | 626 803 |
| Balance sheet — liabilities and equity | ||||||
| Current liabilities | 2 843 407 | 2 675 110 | 2 814 703 | 1 923 451 | 1 898 930 | 1 724 652 |
| Non-current liabilities | — | — | — | — | — | — |
| Total liabilities | 2 843 407 | 2 675 110 | 2 814 703 | 1 923 451 | 1 898 930 | 1 724 652 |
| Share capital | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
| Retained earnings of previous periods | — | −367 117 | −475 491 | −965 361 | −970 561 | −1 094 346 |
| Profit for the year | −367 117 | −108 374 | −355 792 | −5199 | −123 785 | −6003 |
| Total equity | −364 617 | −472 991 | −828 783 | −968 060 | −1 091 846 | −1 097 849 |
| Income statement | ||||||
| Sales revenue | 2 235 973 | 3 554 585 | 3 744 144 | 3 937 194 | 5 564 934 | 5 285 923 |
| Operating profit | −367 118 | −108 375 | −355 794 | −5199 | −123 789 | −6007 |
| EBITDA | −278 223 | 48 764 | −197 675 | −663 | −121 586 | −5655 |
| Profit before income tax | −367 117 | −108 374 | −355 792 | −5199 | −123 785 | −6003 |
| Profit for the reporting year | −367 117 | −108 374 | −355 792 | −5199 | −123 785 | −6003 |
| Labour costs | 50 585 | 39 548 | 96 917 | 135 545 | 205 779 | 253 649 |
| Depreciation of non-current assets | 88 895 | 157 139 | 158 119 | 4536 | 2203 | 352 |
| Other indicators | ||||||
| Employees | 2 | 1 | 2 | 2 | 4 | 5 |
| Calculated dividend | — | 0 | 0 | 134 078 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
CompanyPersonShareholderOther roleAdditional link
Related companies
Same activity — Ravimite jaemüük